Instrument Inactif

Autres langues PHARMING GROUP Euronext Amsterdam

Actions

NL0000377018

Produits pharmaceutiques

Cours en clôture Euronext Amsterdam
- ^EUR	-

14/09	Bourse : Capgemini vend sa division CGS, Euronext reparle consolidation et J&J pourrait céder son orthopédie
14/09	La love story du marché avec l'IA connaît quelques ratés

Autres langues

14/09	FDA approves Pharming's Joenja(R) as first treatment for children with APDS in the U.S.
14/09	Pharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja
11/09	Pharming Receives Fda Approval for Joenja as First Treatment for Children with Apds in the U S
11/09	Pharming krijgt goedkeuring FDA voor nieuwe indicatie Joenja
11/09	FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
11/09	Pharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11
11/09	Pharming krijgt goedkeuring FDA voor nieuwe indicatie Joenja
09/09	Pharming Group to participate in September investor conferences
02/09	Pharming N : Millennium International Management LP - Pharming Group N.V. - Leiden
02/09	Pharming N : Millennium International Management LP - Pharming Group N.V. - Leiden
16/08	Adyen en ABN AMRO blinken uit na cijfers
13/08	Pharming Launches Joenja in Japan for Adult, Pediatric APDS Patients
13/08	Pharming Group Launches Rare Primary Immunodeficiency Therapy Joenja in Japan
13/08	Pharming lanceert Joenja voor APDS-patiënten in Japan
13/08	Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
13/08	Pharming Group Announces Commercial Launch of Joenja in Japan for Adult and Pediatric Patients with Apds Aged 4 and Older
04/08	Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
02/08	Drukke cijferweek op Damrak kent winnaars en verliezers
30/07	Pharming Group's Q2 Earnings, Revenue Fall; 2026 Revenue Outlook Updated
30/07	Pharming Group N.V. Reports Earnings Results for the Half Year Ended June 30, 2026
30/07	Pharming stelt jaaroutlook naar beneden bij
30/07	Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
30/07	Pharming Group N.V. Revises Earnings Guidance for the Year 2026
16/07	Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
14/07	Beleggersvertrouwen naar hoogste niveau in maanden